QUESTION
please follow the uploaded instructions, and please please attached the brochure source to the paper. it is highly important you attach it.
Pharmacology
ANSWER
Pharmacology
Student’s Name
Institutional Affiliation
Course Name and Number
Instructor’s Name
Date
Pharmacology
Part 2
Breast cancer is among the leading causes of death due to cancer among women globally. However, the incidence has increased even in the male counterparts, where cases of breast cancers have been recorded. Treating breast cancers that occur due to mutation in various genes is challenging, and in some cases, there is resistance to endocrine treatment. Under the generic name alpelisib, Piracy was approved by the FDA in 2019 to manage breast cancers in postmenopausal women and men following endocrine treatment resistance (Butler, 2020). Given that it is still a new antineoplastic drug on the market, it is possible that some healthcare professionals have not yet familiarized themselves with it.
Therefore, there is a need to improve on this so that they are fully aware of the drug, how to administer it, the necessary patient education information, and evaluations that should be carried out as a way of monitoring patient progress. The brochure, therefore, targets various healthcare providers, especially those in the oncology department. The information provided in the brochure, although not exhaustive, will significantly help them in their practice as they manage patients with breast cancers, especially those with resistance to endocrine treatment and patients with mutations in the various genes leading to the development of breast cancer. Through this knowledge, they will know how to prescribe the drug and monitor for response and the side effects. This will help in enabling the patients to achieve better health outcomes.
Reference
Butler, S. (2020). Alpelisib (Piqray®). Oncology Times, 42(8), 19. https://journals.lww.com/oncology-times/Fulltext/2020/04200/Alpelisib__Piqray__.10.aspx